Application of intensity-modulated radiotherapy in unresectable poorly differentiated thyroid carcinoma

Fen Xue; Duanshu Li; Chaosu Hu; Zhuoying Wang; Xiayun He; Yi Wu

doi:10.18632/oncotarget.12785

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Application of intensity-modulated radiotherapy in unresectable poorly differentiated thyroid carcinoma

Fen Xue, Duanshu Li, Chaosu Hu, Zhuoying Wang, Xiayun He _ and Yi Wu

PDF | HTML | How to cite

Oncotarget. 2017; 8:15934-15942. https://doi.org/10.18632/oncotarget.12785

Metrics: PDF 1755 views | HTML 2212 views | ?

Abstract

Fen Xue1, Duanshu Li2, Chaosu Hu1, Zhuoying Wang2, Xiayun He1 and Yi Wu2

1 Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

2 Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

Correspondence to:

Xiayun He, email:

Yi Wu, email:

Keywords: unresectable poorly differentiated thyroid carcinoma; intensity modulated radiotherapy; chemotherapy; locoregional control; distant metastases

Received: July 10, 2016 Accepted: October 13, 2016 Published: October 20, 2016

Abstract

Poorly differentiated thyroid carcinoma (PDTC) is a rare and aggressive malignancy with high rates of invasion and distant metastasis. This study was to explore the ability of intensity-modulated radiotherapy (IMRT) combined with chemotherapy to manage unresectable PDTC. Between February 2011 and April 2012, 5 patients with unresectable PDTC were treated by IMRT at our institution and were included in this analysis. The median radiotherapy dose to the gross tumor volume (GTV) was 66 Gy/33 fractions/6.4 weeks. All patients received chemotherapy, and one patient with tumor compression symptoms had a tracheotomy before treatment. The mean survival time of the 5 patients was 41.6 months. The direct causes of death were distant metastases (40%) and progression of the locoregional disease (20%). In conclusion, IMRT combined with chemotherapy for unresectable PDTC might be beneficial to improve locoregional control. Further new therapies are needed to control metastases.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12785

Publication Alerts

Post-Publication Promotion

Publication Discount

Clinical Research Papers:

Application of intensity-modulated radiotherapy in unresectable poorly differentiated thyroid carcinoma

Abstract